The role of exosomes in therapeutic resistance of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) stands as one of the most prevalent malignant tumors globally. Despite considerable advancements in HCC therapies, therapeutic resistance remains a significant challenge that compromises patient prognosis. Increasing evidence indicates that exosomes, which are secreted by cells in the tumor microenvironment (TME), are pivotal players in the development of therapeutic resistance in HCC. These nano-sized vesicles mediate intercellular communication in TME through the transfer of bioactive molecules such as nucleic acids, lipids, and proteins. A comprehensive understanding of the role of exosomes in therapeutic resistance could provide promising strategies for both the diagnosis and treatment of HCC. This review mainly summarizes the involvement of exosomal cargos and elucidates their underlying mechanisms in resistance to therapeutic treatments for HCC, and further discusses the potential clinical applications of exosomes as diagnostic biomarkers and therapeutic targets to overcome drug resistance in HCC.

Keywords

Hepatocellular carcinoma / exosome / therapeutic resistance

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14.

[3] Jiang HY,Xia CC,Duan T.Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis.World J Gastroenterol2018;24:2348-62 PMCID:PMC6000290

[4] Rizzo A,Brandi G.Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing.Future Oncol2020;16:2587-9.

[5] Zhang H,Jiang L.Recent advances in systemic therapy for hepatocellular carcinoma.Biomark Res2022;10:3 PMCID:PMC8744248

[6] Yang C,Zhang L.Evolving therapeutic landscape of advanced hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2023;20:203-22.

[7] Vafaei S,Khanamir RA.Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.Cancer Cell Int2022;22:2 PMCID:PMC8725311

[8] Lee MS,Hsu CH.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.Lancet Oncol2020;21:808-20

[9] Vasan N,Hyman DM.A view on drug resistance in cancer.Nature2019;575:299-309 PMCID:PMC8008476

[10] Ladd AD,Sahin I.Mechanisms of drug resistance in HCC.Hepatology2023;online ahead of print

[11] Gurunathan S,Jeyaraj M,Kim JH.Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes.Cells2019;8:307 PMCID:PMC6523673

[12] Wang X,Lu JY.Exosomes and cancer-diagnostic and prognostic biomarkers and therapeutic vehicle.Oncogenesis2022;11:54 PMCID:PMC9477829

[13] Dai J,Zhong SY.Exosomes: key players in cancer and potential therapeutic strategy.Signal Transduct Target Ther2020;5:145 PMCID:PMC7406508

[14] Zhang PF,Huang XY.Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.Mol Cancer2020;19:110 PMCID:PMC7320583

[15] Xu J,Liang Y.CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.Signal Transduct Target Ther2020;5:298 PMCID:PMC7762756

[16] Lu JC,Huang XY.Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.J Hematol Oncol2021;14:200 PMCID:PMC8627086

[17] Zhou Y,Zhuo H.Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/nuclear factor -kappa B (NF-κB) pathway.Bioengineered2022;13:4786-97 PMCID:PMC8973934

[18] Hao X,Shi X.CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.J Exp Clin Cancer Res2022;41:281 PMCID:PMC9494907

[19] Hu Z,Zhao Y.Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.Mol Cancer2023;22:55 PMCID:PMC10024440

[20] He C,Zhai B.MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Oncotarget2015;6:28867-81 PMCID:PMC4745697

[21] Lou G,Yang F.Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.J Hematol Oncol2015;8:122 PMCID:PMC4627430

[22] Fang T,Lv G.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.Nat Commun2018;9:191 PMCID:PMC5768693

[23] Li W,Li X,Sun Y.Exosomes secreted by M2 macrophages promote cancer stemness of hepatocellular carcinoma via the miR-27a-3p/TXNIP pathways.Int Immunopharmacol2021;101:107585

[24] Wei XC,Zhou P.Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma.World J Gastroenterol2021;27:8302-22 PMCID:PMC8717014

[25] Gao Y,Qi Y.Golgi phosphoprotein 3 promotes angiogenesis and sorafenib resistance in hepatocellular carcinoma via upregulating exosomal miR-494-3p.Cancer Cell Int2022;22:35 PMCID:PMC8785582

[26] Nakano T,Chen IH.Overexpression of miR-4669 enhances tumor aggressiveness and generates an immunosuppressive tumor microenvironment in hepatocellular carcinoma: its clinical value as a predictive biomarker.Int J Mol Sci2023;24:7908 PMCID:PMC10177802

[27] Takahashi K,Wood J,Patel T.Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy.Mol Cancer Res2014;12:1377-87 PMCID:PMC4201956

[28] Takahashi K,Kogure T,Patel T.Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.FEBS Open Bio2014;4:458-67 PMCID:PMC4050189

[29] Tey SK,Chan JYT.Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.J Hepatol2022;76:883-95

[30] Wang X,Sze KM.S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos.Gut2023;72:1370-84 PMCID:PMC10314046

[31] Qu Z,Wu J,Jiang C.Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.J Exp Clin Cancer Res2016;35:159 PMCID:PMC5045585

[32] Huang H,Liu K.RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.J Gastroenterol Hepatol2021;36:3429-37.

[33] Tang Z,Zou J,Sun X.Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC.PeerJ2021;9:e11200 PMCID:PMC8051335

[34] Negri M,Gentile A.Vitamin D Reverts the exosome-mediated transfer of cancer resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma.Front Oncol2022;12:874091 PMCID:PMC9083073

[35] Huang A,Chung WY,Zhou J.Targeted therapy for hepatocellular carcinoma.Signal Transduct Target Ther2020;5:146 PMCID:PMC7419547

[36] Chen J,Zhao J.Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.Cancer Lett2015;367:1-11

[37] Kudo M,Takayama T.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.J Gastroenterol2016;51:1150-60 PMCID:PMC5121182

[38] Galle PR.Sorafenib in advanced hepatocellular carcinoma - we have won a battle not the war.J Hepatol2008;49:871-3

[39] Keating GM.Sorafenib: a review of its use in advanced hepatocellular carcinoma.Drugs2009;69:223-40

[40] Ping L. Sorafenib plus capecitabine for patients with advanced hepatocellular carcinoma. Available from: https://www.semanticscholar.org/paper/Sorafenib-plus-Capecitabine-for-Patients-with-Ping/7ac9d458ad5c48b9f13dbff60eb7b2f45084854c?utm_source=direct_link [Last accessed on 27 Oct 2023]

[41] Bruix J,Merle P.RESORCE InvestigatorsRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66.

[42] Zhi Y,Zhou H.FOXM1-mediated LINC-ROR regulates the proliferation and sensitivity to sorafenib in hepatocellular carcinoma.Mol Ther Nucleic Acids2019;16:576-88 PMCID:PMC6514537

[43] Zhang Y.Functions of immune checkpoint molecules beyond immune evasion. In: Xu J, editor. Regulation of cancer immune checkpoints. Singapore: Springer; 2020. pp. 201-26.

[44] Llovet JM,Heikenwalder M.Immunotherapies for hepatocellular carcinoma.Nat Rev Clin Oncol2022;19:151-72

[45] Sangro B,Hervás-stubbs S.Advances in immunotherapy for hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2021;18:525-43. PMCID:PMC8042636

[46] Wang Z,Gao P.Immune checkpoint inhibitor resistance in hepatocellular carcinoma.Cancer Lett2023;555:216038.

[47] Chen G,Zhang W.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.Nature2018;560:382-6.

[48] Poggio M,Pai CC.Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory.Cell2019;177:414-27.e13 PMCID:PMC6499401

[49] Yang Y,Chan LC.Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.Cell Res2018;28:862-4 PMCID:PMC6082826

[50] Ye L,Cheng Y.Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1⁺ regulatory B cell expansion.J Immunother Cancer2018;6:145 PMCID:PMC6288912

[51] Wang X,Zhangyuan G.14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes.Cell Death Dis2018;9:159 PMCID:PMC5833352

[52] Pu J,Nian J.M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway.Cell Death Discov2021;7:182 PMCID:PMC8289864

[53] Xue D,Liang Z.Current perspectives on the unique roles of exosomes in drug resistance of hepatocellular carcinoma.J Hepatocell Carcinoma2022;9:99-112. PMCID:PMC8863332

[54] El-Awady R,Hashim A.The Role of eukaryotic and prokaryotic ABC transporter family in failure of chemotherapy.Front Pharmacol2016;7:535. PMCID:PMC5223437

[55] Chen Z,Zhang L.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade.Cancer Lett2016;370:153-64

[56] Bebawy M,Lee E.Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells.Leukemia2009;23:1643-9.

[57] Levchenko A,Niu X.Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells.Proc Natl Acad Sci U S A2005;102:1933-8 PMCID:PMC545583

[58] Sousa D,Vasconcelos MH.Intercellular transfer of cancer drug resistance traits by extracellular vesicles.Trends Mol Med2015;21:595-608.

[59] Yu Y.Radiotherapy for hepatocellular carcinoma.Semin Radiat Oncol2018;28:277-87

[60] Bang A.Radiotherapy for HCC: ready for prime time?.JHEP Rep2019;1:131-7 PMCID:PMC7001576

[61] Wu Y,Wang R.Molecular mechanisms of tumor resistance to radiotherapy.Mol Cancer2023;22:96 PMCID:PMC10268375

[62] Barker HE,Khan AA.The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.Nat Rev Cancer2015;15:409-25. PMCID:PMC4896389

[63] Fan Q,Zhou Y,Wu C.An emerging role of radiation‑induced exosomes in hepatocellular carcinoma progression and radioresistance (Review).Int J Oncol2022;60:46 PMCID:PMC8923655

[64] He D,Fu B.Exosomes participate in the radiotherapy resistance of cancers.Radiat Res2022;197:559-65

[65] Ni J,Malouf D,Graham P.Exosomes in cancer radioresistance.Front Oncol2019;9:869 PMCID:PMC6742697

[66] Ohri N,Krishnan S.Radiotherapy for hepatocellular carcinoma: new indications and directions for future study.J Natl Cancer Inst2016;108:djw133. PMCID:PMC6279296

[67] Arnold CR,Skvortsova II.The role of cancer stem cells in radiation resistance.Front Oncol2020;10:164 PMCID:PMC7044409

[68] Pu X,Gao Y,Chang P.Mesenchymal stem cell-derived exosomes: biological function and their therapeutic potential in radiation damage.Cells2020;10:42 PMCID:PMC7823972

[69] Yang Z,Yang L,Luo Y.The emerging role of exosomes in radiotherapy.Cell Commun Signal2022;20:171 PMCID:PMC9620591

[70] Fang X,Liu S.Cancer stem cells in hepatocellular carcinoma: intrinsic and extrinsic molecular mechanisms in stemness regulation.Int J Mol Sci2022;23:12327 PMCID:PMC9604119

[71] Lee TK,Ma S.Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.Nat Rev Gastroenterol Hepatol2022;19:26-44

[72] Ma S,Zheng BJ,Guan XY.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.Oncogene2008;27:1749-58

[73] Dongre A.New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.Nat Rev Mol Cell Biol2019;20:69-84

[74] Syn N,Sethi G,Goh BC.Exosome-mediated metastasis: from epithelial-mesenchymal transition to escape from immunosurveillance.Trends Pharmacol Sci2016;37:606-17

[75] Chen L,He Y.HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway.Cell Death Dis2018;9:513 PMCID:PMC5938707

[76] Karaosmanoğlu O,Sivas H.Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.Cell Oncol2018;41:439-53

[77] Shi CJ,Deng LQ,Fu WM.Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinoma.Cell Biol Toxicol2023;39:1735-52

[78] Lin Q,Bai MJ.Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis.Am J Transl Res2020;12:1080-95 PMCID:PMC7137059

[79] Sun H,Hu B.Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.Signal Transduct Target Ther2021;6:187 PMCID:PMC8149717

[80] He R,Shi W.Exosomes in hepatocellular carcinoma microenvironment and their potential clinical application value.Biomed Pharmacother2021;138:111529

[81] Wu Y,Li Q.Autophagy, an accomplice or antagonist of drug resistance in HCC?.Cell Death Dis2021;12:266 PMCID:PMC7954824

[82] Liu L,He XX.The role of autophagy in hepatocellular carcinoma: friend or foe.Oncotarget2017;8:57707-22 PMCID:PMC5593678

[83] Huang F,Wang YG.Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma.World J Gastroenterol2018;24:4643-51 PMCID:PMC6224467

[84] Shi YH,Zhou J.Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.Autophagy2011;7:1159-72.

[85] Zhang K,Zhou H.PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.Cell Death Dis2018;9:312 PMCID:PMC5833744

[86] Guo XL,Sun K.Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.J Mol Med2013;91:473-83 PMCID:PMC3611041

[87] Liu DX,Guo JP.Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy.Oncol Lett2019;17:323-31 PMCID:PMC6313222

[88] Tian XP,Jin XH.Acidic microenvironment up-regulates exosomal mir-21 and mir-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis.Theranostics2019;9:1965-79 PMCID:PMC6485281

[89] Yao M,Cheng B.Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine.Front Pharmacol2023;14:1110922. PMCID:PMC9886889

[90] Huang M,Huang N.Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells.Cancer Sci2022;113:1968-83 PMCID:PMC9207376

[91] Li C.Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma.Cell Mol Life Sci2019;76:4203-19

[92] Yao Z,Tai Y.Serum exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma.Aging2020;12:11843-63 PMCID:PMC7343450

[93] Ji W,Ke Y.Exosomal ZFPM2-AS1 contributes to tumorigenesis, metastasis, stemness, macrophage polarization, and infiltration in hepatocellular carcinoma through PKM mediated glycolysis.Environ Toxicol2023;38:1332-46

[94] Hoshino A,Bojmar L.Extracellular vesicle and particle biomarkers define multiple human cancers.Cell2020;182:1044-61.e18.

[95] Li R,Jiang K.Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux.Carcinogenesis2020;41:1583-91

[96] Zhang H,Liu J,Lu A.Advances in the discovery of exosome inhibitors in cancer.J Enzyme Inhib Med Chem2020;35:1322-30 PMCID:PMC7717571

[97] Kim JH,Baek MC.Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer.Exp Mol Med2022;54:1833-43. PMCID:PMC9707221

[98] Xu R,Chen M,Greening DW.Extracellular vesicles in cancer - implications for future improvements in cancer care.Nat Rev Clin Oncol2018;15:617-38

[99] Meng W,Hao Y,Li L.Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source.Drug Deliv2020;27:585-98 PMCID:PMC7178886

[100] Herrmann IK,Fuhrmann G.Extracellular vesicles as a next-generation drug delivery platform.Nat Nanotechnol2021;16:748-59

[101] Gilligan KE.Engineering exosomes for cancer therapy.Int J Mol Sci2017;18:1122 PMCID:PMC5485946

[102] Lou G,Xia C.MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway.J Exp Clin Cancer Res2020;39:4 PMCID:PMC6941283

[103] Li H,Shi Y.Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma.J Nanobiotechnol2018;16:103 PMCID:PMC6300915

[104] Deng J.Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.Oncoimmunology2023;12:2152635 PMCID:PMC9809939

[105] He C,Qi Y.Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.J Nanobiotechnol2023;21:154. PMCID:PMC10193671

[106] Kim MS,Zhao Y.Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.Nanomedicine2016;12:655-64. PMCID:PMC4809755

[107] Chen T,Wang X,Huang B.Asiatic acid encapsulated exosomes of hepatocellular carcinoma inhibit epithelial-mesenchymal transition through transforming growth factor beta/smad signaling pathway.J Biomed Nanotechnol2021;17:2338-50.